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Introduction
Prognostic biomarkers in a disease provide information
regarding outcome irrespective of therapy. Candidate
prognostic biomarkers in breast cancer include elevated
levels of expression of proliferation indices such as Ki67
and proliferating cell nuclear antigen; expression of estro-
gen receptor (ER) and progesterone receptor; amplifica-
tion and over-expression of HER2, cyclin D1, and c-myc;
p53 nuclear protein accumulation; bcl-2 expression; and
alteration in angiogenesis proteins such as vascular
endothelial growth factor [1–5]. In particular, review of the
literature suggests that over-expression of HER2 and p53
may have prognostic significance in breast cancer. HER2
(c-erbB2) encodes a membrane protein (p185) that is
tyrosine phosphorylated after interaction with its ligands.
Over-expression of HER2 occurs through either amplifica-
tion of the gene or mRNA over-expression. p53 is involved
in regulating cell proliferation, inducing apoptosis, and in
promoting chromosomal stability. Disruption of these func-
tions appears to play an important role in carcinogenesis.
There is evidence that over-expression of HER2 and p53
is involved in breast cancer progression [6]. This hypothe-
CMF = cyclophosphamide, methotrexate, and fluorouracil; ER = estrogen receptor.
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Abstract
Introduction: Many laboratories are currently evaluating the
usefulness of determination of HER2, p53, and Ki67
proliferation indices using immunohistochemical techniques
in cancer. Although the available studies suggest that these
factors might indeed be helpful in making treatment
decisions in cancer patients, their clinical usefulness is still
controversial.
Methods: Expression of HER2, p53, and Ki67 was examined
by immunohistochemistry in samples of breast tissue from
506 patients with invasive ductal carcinoma, obtained between
1981 and 1999 (median follow up period 82 months), and their
significance for prognosis was analyzed.
Results: Of the 506 carcinoma tissue samples, 20.1%, 29.0%,
and 53.6% were positive for HER2 over-expression, p53
protein accumulation, and Ki67 expression, respectively. Over-
expression of HER2 significantly reduced disease free
(P=0.02) and overall survival (P=0.005). Accumulation of p53
protein significantly decreased disease free (P=0.01) and
overall survival (P=0.01). Patients with tumors that were
positive for both HER2 and p53 relapsed and died within a
significantly shorter period of time after surgery (P=0.0001
and P<0.0001, respectively). In multivariate analysis, patients
with both HER2 and p53 positive tumors had considerably
decreased overall survival (P=0.04), as did patients with larger
tumor size and positive lymph node status.
Conclusion: The findings of the present study indicate that the
coexistence of HER2 over-expression and p53 protein
accumulation is a strong prognostic molecular marker in breast
cancer.
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sis is based on the high frequency of HER2 and p53 over-
expression among invasive and noninvasive breast
cancers and among benign breast diseases [7–9]. This
suggests that HER2 and p53 play roles in the early stages
of breast tumorigenesis.
In the present study we examined the expression of HER2,
p53, and Ki67 in samples of breast tissue from
506 patients with invasive ductal carcinoma, obtained
between 1981 and 1999, and analyzed their significance
for prognosis. Our results indicate that the coexistence of
HER2 over-expression and accumulation of p53 protein is
a strong prognostic molecular marker in breast cancer.
Methods
Patients and breast cancer tissues
Breast tumor specimens from 506 female patients with
primary invasive ductal carcinoma who were treated at
Nagoya City University Hospital between 1981 and 1999
were included in the present study (Table 1). All patients
had undergone mastectomy or lumpectomy. After surgery,
27% of patients received no additional therapy. Of the
remaining patients, 20% received systemic adjuvant
therapy consisting of endocrine therapy (tamoxifen) alone,
17% received chemotherapy alone, and 36% received
combined endocrine therapy and chemotherapy. Patients
who were positive for axillary lymph nodes received either
oral administration of 5-fluorouracil derivatives for 2 years
or a combination of cyclophosphamide, methotrexate, and
fluorouracil (CMF). Patients were observed for disease
recurrence and death at least once every 6 months for
5 years after surgery and yearly thereafter. The median
follow-up period was 82 months (range 2–249 months).
Immunohistochemical analysis for estrogen receptor-α α,
HER2, p53, and Ki67
One 4-µm section from each submitted paraffin block was
first stained with hematoxylin and eosin in order to verify
that an adequate number of invasive ductal carcinoma
cells were present and that quality of fixation was suffi-
cient for immunohistochemical analysis. Serial sections
(4-µm) were prepared from selected blocks and float
mounted on adhesive coated glass slides for ER-α, HER2,
p53, or Ki67 staining. Primary antibodies included mono-
clonal mouse antihuman estrogen receptor antibody (1D5;
DAKO, Glostrup, Denmark) at 1:100 dilution for ER-α,
rabbit antihuman c-erbB2 oncoprotein antibody (DAKO)
at 1:200 dilution for HER2, monoclonal mouse antihuman
p53 protein antibody (PAb1801; Novocastra, Newcastle,
UK) at 1:50 dilution for p53, and monoclonal mouse anti-
human Ki67 antibody (MIB-1; DAKO) at 1:100 dilution for
Ki67. The DAKO EnVision system (DAKO EnVision
labelled polymer, peroxidase) was used as the detection
system for ER-α, HER2, and Ki67. The streptavidin-biotin
system (SAB-PO kit; Nichirei Co., Inc., Tokyo, Japan) was
applied for detection of the bound antibody of p53.
Immunohistochemical scoring
Immunostained slides were scored after the entire slide
had been evaluated by light microscopy. The expression of
ER-α was scored by assigning a proportion score and an
intensity score according to Allred’s procedure [10]. Any
brown nuclear staining in invasive breast epithelium was
counted toward the proportion score. Tumors with scores
of 3 or greater were considered to be positive for ER-α
expression. HER2 immunostaining was evaluated using
the same method as is employed by the HercepTest
(DAKO). To determine the score of HER2 expression the
membrane staining pattern was estimated and scored on
a scale of 0 to 3+. Tumors with scores of 2 or greater
were considered to be positive for HER2 over-expression.
The expression status of p53 and Ki67 was assessed
according to the estimated proportion of nuclear staining
Table 1
Clinicopathologic characteristics of patients with invasive
ductal carcinoma
Parameter Value (n [%])
n 506
Age at diagnosis (years)
≤ 50 211 (42)
> 50 295 (58)
Age range (years) 22–91
Tumor size (cm)
< 2 209 (41)
≥ 2 295 (59)
Number of positive lymph nodes
0 276 (57)
1–3 115 (24)
> 3 93 (19)
Histological grade
1 93 (17)
2 291 (59)
3 116 (24)
Adjuvant therapy
None 137 (27)
Endocrine therapy 101 (20)
Chemotherapy 85 (17)
Combined 183 (36)
Follow up (months)
Mean 91
Median 82
Range 2–249Breast Cancer Research    Vol 6 No 1 Yamashita et al.
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of tumor cells that were positively stained. Scoring criteria
for p53 were as follows (in the form proportion of nuclear
staining=score): none=0, <1/10=1, 1/10–1/2=2, and
>1/2=3. Scoring criteria for Ki67 were as follows (in the
form proportion of nuclear staining=score): none=0,
<1/100=1, 1/100–1/10=2, 1/10–1/2=3, and
>1/2=4. Tumors with a score of 1 or greater for p53
were considered to be positive for p53 protein accumula-
tion, and tumors with a score of 2 or greater for Ki67 were
considered to be positive for Ki67 expression.
Statistical analysis
The  χ2 test was used to compare immunohistochemical
results for molecular markers with clinicopathologic charac-
teristics. Estimation of disease free and overall survival was
performed using the Kaplan–Meier method, and differ-
ences between survival curves were assessed with the log-
rank test. Cox’s proportional hazards model was used for
univariate and multivariate analyses of prognostic values.
Results
Relationship between HER2, p53, and Ki67 expression
and clinicopathologic factors
Of the 506 primary invasive ductal carcinomas, 20.1%,
29.0% and 53.6% were positive for HER2 over-expres-
sion, p53 protein accumulation, and Ki67 expression,
respectively (Table 2). HER2 over-expression was signifi-
cantly correlated with tumor size (P=0.004), number of
positive lymph nodes (P=0.006), and histological grade
(P<0.0001), and an inverse association was found
between HER2 over-expression and ER-α expression
(P<0.0001). Significant associations were observed
between p53 positivity and tumor size (P=0.0009), histo-
logical grade (P<0.0001), and negativity for ER-α
(P<0.0001). Ki67 expression was significantly correlated
with histological grade (P=0.004), whereas no associa-
tion was found between Ki67 expression and tumor size,
number of positive lymph nodes, or ER-α expression.
There were 339 ER-α positive tumors (67.7%), and
inverse associations were observed between ER-α
expression and tumor size (P=0.01) and histological
grade (P<0.0001).
Correlation between HER2 over-expression, p53 protein
accumulation, and Ki67 expression
Over-expression of HER2 was significantly associated
with p53 protein accumulation (P<0.0001), but not with
Ki67 expression (Table 3). In contrast, a significant associ-
ation was observed between expression status of p53 and
that of Ki67 (P<0.0001).
Disease free and overall survival categorized by HER2,
p53, and Ki67 expression
HER2 over-expression was associated with significantly
reduced disease free (P=0.02) and overall survival
(P=0.005; Fig.1). Similarly, p53 protein accumulation
Table 2
Correlation between clinicopathologic factors and molecular markers
HER2 p53 Ki67
Parameter Positive/total (n [%]) P Positive/total (%) P Positive/total (%) P
Total 104/503 (20.1) 145/500 (29.0) 268/500 (53.6)
Tumor size (cm)
<2.0 30/208 (14.4) 0.004 44/209 (21.1) 0.0009 110/209 (52.6) NS
≥2.0 74/295 (25.1) 101/291 (34.7) 158/291 (54.3)
Number of positive lymph nodes
0 47/276 (17.0) 0.006 72/274 (26.3) NS 145/274 (52.9) NS
1–3 21/115 (18.3) 32/114 (28.1) 62/114 (54.4)
>3 30/93 (32.3) 36/92 (39.1) 48/92 (52.2)
Histological grade
1 5/93 (5.4) <0.0001 7/91 (7.7) <0.0001 39/91 (42.9) 0.004
2 291/58 (19.9) 82/291 (28.2) 151/291 (51.9)
3 40/116 (34.5) 55/116 (47.4) 76/116 (65.5)
Estrogen receptor-α
Negative 70/163 (42.9) <0.0001 77/162 (47.5) <0.0001 90/162 (55.6) NS
Positive 34/339 (10.0) 68/340 (20.0) 179/340 (52.6)
NS, not significant.was associated with significantly reduced disease free
(P=0.01) and overall survival (P=0.01; Fig.2). Both the
disease free and overall survival curves were similar
between the tumors positive for HER2 over-expression
and the tumors positive for p53 protein accumulation
(compare Fig.1a with Fig.2a, and Fig.1b with Fig.2b). In
particular, significantly more patients with tumors that
were negative for HER2 or p53 had been alive within
10 years after surgery (Figs1b and 2b). On the other
hand, there was no relation between Ki67 expression
status and overall survival, whereas Ki67 expression was
associated with significantly decreased disease free sur-
vival (P=0.001; Fig.3). The tumors of 47 patients were
positive for both HER2 over-expression and p53 protein
accumulation. The disease free and overall survival curves
demonstrate that these patients relapsed and died within
a significantly shorter period of time after the surgery
(Fig.4;  P=0.0001). Interestingly, the disease free and
overall survival curves for patients with HER2 or p53 posi-
tive tumors were very similar to those for patients with
tumors that were negative for both HER2 and p53 (Fig.4).
Prognostic analysis of disease free survival
In the univariate analysis (Table 4), combined HER2 and
p53 status (P<0.0001) and Ki67 status (P=0.001), as
well as tumor size (P<0.0001), number of positive lymph
nodes (P<0.0001), histological grade (P<0.0001), ER-α
expression (P=0.03), and the type of adjuvant therapy
(P<0.0001) were strongly able to predict disease free sur-
vival. Multivariate analysis showed reduced disease free
survival with increasing tumor size (P=0.02), increasing
number of positive lymph nodes (P<0.0001), and positive
Ki67 status (P=0.003). There was no significant relation
between disease free survival and combined HER2 and
p53 status, histological grade, ER-α expression, and the
type of adjuvant therapy in multivariate analysis (Table 4).
Prognostic analysis of overall survival
Univariate analysis (Table 5) demonstrated significant
associations between overall survival and combined HER2
and p53 status (P<0.0001), as well as tumor size
(P<0.0001), number of positive lymph nodes
(P<0.0001), histological grade (P<0.0001), ER-α
expression (P=0.002), and the type of adjuvant therapy
(P=0.0001). There was no significant relation between
Ki67 expression status and overall survival. In multivariate
analysis, patients with HER2 and p53 positive tumors
(P=0.04), as well as patients with larger tumor size
(P=0.008) and positive lymph node status (P<0.0001),
had significantly reduced overall survival (Table 5). There
was no significant relation between overall survival and
histological grade, ER-α expression, and the type of adju-
vant therapy in multivariate analysis.
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Table 3
Correlation between HER2, p53, and Ki67 expression
p53 Ki67
Parameter Positive/total (%) P Positive/total (%) P
HER2
Negative 96/398 (24.1) <0.0001 211/398 (53.0) NS
Positive 49/103 (47.6) 57/103 (55.3)
p53
Negative 168/357 (47.1) <0.0001
Positive 101/145 (69.7)
Figure 1
Effect of HER2 over-expression on (a) disease free and (b) overall survival among 497 patients with invasive ductal carcinoma. Disease free and
overall survival were significantly better in patients with HER2 negative tumors than in patients with HER2 positive tumors (P=0.02 and
P=0.0005, respectively).Breast Cancer Research    Vol 6 No 1 Yamashita et al.
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Figure 2
Effect of p53 protein accumulation on (a) disease free and (b) overall survival among 494 patients with invasive ductal carcinoma. Disease free
and overall survival were significantly better in patients with p53 negative tumors than in patients with p53 positive tumors (P=0.01 for both).
Figure 3
Effect of Ki67 expression on (a) disease free and (b) overall survival among 494 patients with invasive ductal carcinoma. Disease free survival was
significantly better in patients with Ki67 negative tumors than in patients with Ki67 positive tumors (P=0.001).
Figure 4
Effect of coexistence of HER2 over-expression and p53 protein accumulation on (a) disease free and (b) overall survival among 494 patients with
invasive ductal carcinoma. Disease free and overall survival were significantly worse in patients with HER2 and p53 positive tumors than in patients
with HER2 and p53 negative tumors and HER2 or p53 positive tumors (P=0.0001 for both).Discussion
The present study indicates that the coexistence of HER2
over-expression and p53 protein accumulation has strong
prognostic significance in invasive ductal carcinoma of the
breast after a median follow-up period of 82 months.
HER2 encodes a 185-kDa transmembrane glycoprotein
with intracellular tyrosine kinase activity that belongs to the
epidermal growth factor receptor family [11]. Although no
ligand has been identified for HER2, several peptide
growth factors bind to the other members of the family.
Amplification or over-expression of HER2 is observed in
20–40% of human breast cancers. The prognostic signifi-
cance of HER2 over-expression was first reported in 1987
[12]. Subsequently, over 200 studies have been reported
in which the role of amplification/over-expression of HER2
was investigated as a prognostic marker in breast cancer.
Also, we previously reported that HER2 amplification was
strongly associated with both disease free and overall sur-
vival in breast cancer [5]. In the present study we
extended our analysis of HER2 over-expression to more
than 500 invasive ductal tumors, and showed that over-
expression of HER2 was associated with poor prognosis.
Nearly one-third of breast cancers have mutations in the
p53 gene, which are associated with high histological
grade and clinical aggressiveness [3]. Immunohistochemi-
cal assays generally detect nuclear accumulation of the
protein, which is often related to conformational alterations
and a prolonged half-life of the encoded protein [13,14].
Accumulation of p53 protein was significantly associated
with poor prognosis in our study and in other studies of
patients with breast cancer [15,16]. These studies suggest
both a prognostic and a predictive role for p53 [1].
Tumors with both HER2 over-expression and p53 protein
accumulation were reported in several studies, and
patients with such tumors were found to have poor prog-
nosis [17–22]; the findings reported here also indicate
that both HER2 over-expression and p53 protein accumu-
lation are associated with markedly poorer disease free
and overall survival. On the other hand, some studies have
shown a better prognosis in patients with breast cancers
with HER2 overexpression and p53 protein accumulation
[23]. These differences may reflect the effect of various
therapeutic regimens.
Most patients with early breast cancer receive adjuvant
treatment, and the identification of predictive factors may
help in selecting the optimal therapeutic strategy for individ-
ual patients. HER2 over-expression may be associated with
reduced efficacy of adjuvant endocrine therapy with tamox-
ifen [24–26]. The role of p53 mutations in the efficacy of
endocrine therapy is still under evaluation. On the other
hand, previous data suggested that HER2 positive tumors
might be resistant to adjuvant treatment with CMF [27,28].
There is evidence that women whose tumors over-express
HER2 are likely to derive greater benefit from therapy with
anthracycline-containing regimens than from alkylating
agents [25,29–31]. It was also reported that patients with
both HER2 and p53 positive tumors had an improved
10-year survival when treated with a high dose FAC (fluo-
rouracil, doxorubicin, cyclophosphamide) regimen [29]. The
patients included in the present study were treated with
tamoxifen, fluorouracil, or a CMF regimen, and anthracycline
based chemotherapy was not used. Further studies are
needed to determine which endocrine or chemotherapeutic
agents should be used in breast cancers with different
expression profiles, especially in patients with poor prognosis.
Conclusion
We examined the expression of HER2, p53, and Ki67 in
506 invasive ductal carcinoma tissue samples. The results
indicate that the coexistence of HER2 over-expression
and p53 protein accumulation is a strong prognostic mol-
ecular marker in breast cancer.
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Table 4
Prognostic factors in 470 invasive ductal carcinomas compared
with disease free survival
Univariate Multivariate
Parameter PP RR (95% CI)
Tumor size <0.0001 0.02 0.626 (0.418–0.938)
Number of <0.0001 <0.0001 0.227 (0.144–0.359)
positive lymph nodes
Histological grade <0.0001 0.09 0.712 (0.479–1.057)
Estrogen receptor-α 0.03 0.42 1.176 (0.787–1.756)
HER2/p53 <0.0001 0.06 0.630 (0.391–1.017)
Ki67 0.001 0.003 0.589 (0.416–0.833)
Adjuvant therapy <0.0001 0.76 1.098 (0.606–1.988)
CI, confidence interval; RR, relative risk.
Table 5
Prognostic factors in 470 invasive ductal carcinomas compared
with overall survival
Univariate Multivariate
Parameter PP RR (95% CI)
Tumor size <0.0001 0.008 0.470 (0.273–0.809)
Number of positive <0.0001 <0.0001 0.275 (0.157–0.482)
lymph nodes
Histological grade <0.0001 0.09 0.665 (0.419–1.056)
Estrogen receptor-α 0.002 0.16 1.389 (0.866–2.229)
HER2/p53 <0.0001 0.04 0.565 (0.323–0.990)
Ki67 0.28
Adjuvant therapy 0.0001 0.75 0.879 (0.400–1.930)
CI, confidence interval; RR, relative risk.Breast Cancer Research    Vol 6 No 1 Yamashita et al.
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